(3R,4S)-Tofacitinib - CAS 1092578-46-5
Catalog number:
1092578-46-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H20N6O
Molecular Weight:
312.37
COA:
Inquire
Targets:
JAK
Description:
Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CP-690550
MSDS:
Inquire
1.Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).
Jiang JK1, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ. J Med Chem. 2008 Dec 25;51(24):8012-8. doi: 10.1021/jm801142b.
Here, we examine the significance that stereochemistry plays within the clinically relevant Janus kinase 3 (Jak3) inhibitor 1 (CP-690,550). A synthesis of all four enantiopure stereoisomers of the drug was carried out and an examination of each compound revealed that only the enantiopure 3R,4R isomer was capable of blocking Stat5 phosphorylation (Jak3 dependent). Each compound was profiled across a panel of over 350 kinases, which revealed a high level of selectivity for the Jak family kinases for these related compounds. Each stereoisomer retained a degree of binding to Jak3 and Jak2 and the 3R,4S and 3S,4R stereoisomers were further revealed to have binding affinity for selected members of the STE7 and STE20 subfamily of kinases. Finally, an appraisal of the minimum energy conformation of each stereoisomer and molecular docking at Jak3 was performed in an effort to better understand each compounds selectivity and potency profiles.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


NS-018
(CAS: 1239358-86-1)

NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

Itacitinib
(CAS: 1334298-90-6)

Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...

CAS 1056636-07-7 CYT387 Mesylate

CYT387 Mesylate
(CAS: 1056636-07-7)

CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 2098466-94-3 TYK2-IN-2

TYK2-IN-2
(CAS: 2098466-94-3)

TYK2-IN-2 is an inhibitor of TYK2 with potential for the treatment of inflammatory and autoimmune diseases.

CAS 1056636-06-6 CYT387 sulfate salt

CYT387 sulfate salt
(CAS: 1056636-06-6)

CYT387 sulfate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 1092578-47-6 (3S,4S)-Tofacitinib

(3S,4S)-Tofacitinib
(CAS: 1092578-47-6)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 211555-05-4 WHI-P97

WHI-P97
(CAS: 211555-05-4)

WHI-P97 is a potent cell-permeable and specific inhibitor of JAK3(IC50 = 11 μM). Inhibits JAK3 in immune complex kinase assaysin a dose-dependent fashion and re...

CAS 1092499-93-8 NVP-BSK805

NVP-BSK805
(CAS: 1092499-93-8)

NVP-BSK805, a quinoxaline derivative, is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis (GI50 < 100 nM) and restrain the growth of JAK2...

CAS 1187595-84-1 Baricitinib phosphate

Baricitinib phosphate
(CAS: 1187595-84-1)

IC50 Value: JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nan...

CAS 937272-79-2 Pacritinib

Pacritinib
(CAS: 937272-79-2)

Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...

CAS 916742-11-5 R-932348

R-932348
(CAS: 916742-11-5)

A dual JAK/SYK inhibitor that can be used to treat diseases and disorders of the eye.

BBT594
(CAS: 882405-89-2)

BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...

CAS 1208319-27-0 Oclacitinib maleate

Oclacitinib maleate
(CAS: 1208319-27-0)

Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).

CAS 273727-89-2 ZM 39923

ZM 39923
(CAS: 273727-89-2)

ZM 39923 inhibits Janus kinase (IC50=10 nM).

CAS 80418-25-3 20(S)-Notoginsenoside R2

20(S)-Notoginsenoside R2
(CAS: 80418-25-3)

20(S)-Notoginsenoside R2 is a natural product extracted from the roots of Panax notoginseng (Burk.) F.H.Chen. It has neuroprotection against 6-OHDA-induced neur...

CAS 941685-37-6 Ruxolitinib S enantiomer

Ruxolitinib S enantiomer
(CAS: 941685-37-6)

Ruxolitinib S enantiomer, the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor to enter the clinic. It...

PF-956980
(CAS: 1262832-74-5)

PF-956980, a close analogue of Tofacitinib, is a JAK3-selective inhibitor used as an anti-inflammatory agent. Besides, some studies showed that PF-956980 striki...

NS-018 hydrochloride
(CAS: 1239358-85-0)

The hydrochloride salt form of NS-018 which is a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tum...

CAS 1206161-97-8 Filgotinib

Filgotinib
(CAS: 1206161-97-8)

Filgotinib, also known as GLPG0634, is a potent and selective JAK1 inhibitor. Filgotinib displayed a selectivity of 30-fold for JAK1- over JAK2-dependent signal...

Chemical Structure

CAS 1092578-46-5 (3R,4S)-Tofacitinib

Quick Inquiry

Verification code

Featured Items